FDA Committee Recommends Amgen’s Enbrel For Approval In Pediatric Psoriasis
This article was originally published in The Pink Sheet Daily
Executive Summary
Panel sees benefit of giving physicians freedom to choose the treatment and gaining further data through Amgen’s proposed safety registry and ongoing study.
You may also be interested in...
Sandoz’s Erelzi: Biosimilar Pediatric Labeling Strayed From Enbrel
Drug Review Profile of TNF-inhibitor etanercept-szzs examines how US FDA navigated its way around ‘inaccurate’ pediatric psoriasis labeling for the reference product, Amgen’s Enbrel, to reflect current state of the knowledge on the biosimilar’s labeling, albeit only temporarily.
Sandoz’s Erelzi: Biosimilar Pediatric Labeling Strayed From Enbrel
Drug Review Profile of TNF-inhibitor etanercept-szzs examines how US FDA navigated its way around ‘inaccurate’ pediatric psoriasis labeling for the reference product, Amgen’s Enbrel, to reflect current state of the knowledge on the biosimilar’s labeling, albeit only temporarily.
FDA Panel Unanimously Recommends Centocor’s Ustekinumab
But Dermatologic and Ophthalmic Drugs panel says the proposal for long-term safety follow-up is inadequate.